Perspectives in Clinical Hepatology

You have full text access to this OnlineOpen article

Global challenges in liver disease†‡

  1. Roger Williams§,*

Article first published online: 29 AUG 2006

DOI: 10.1002/hep.21347

Issue

Hepatology

Hepatology

Volume 44, Issue 3, pages 521–526, September 2006

Additional Information

How to Cite

Williams, R. (2006), Global challenges in liver disease. Hepatology, 44: 521–526. doi: 10.1002/hep.21347

Author Information

  1. UCL Institute of Hepatology, Division of Medicine, Royal Free and University College Medical School, London, UK

  1. §

    fax: (44) 207 380 0405

*The UCL Institute of Hepatology, Royal Free and University College Medical School, 69-75 Chenies Mews, London, WC1E 6HX, UK

  1. †

    Based on Presidential Lecture given at the Shanghai–Hong Kong International Liver Congress 2006.

  2. ‡

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 29 AUG 2006
  2. Article first published online: 29 AUG 2006
  3. Manuscript Accepted: 19 JUL 2006
  4. Manuscript Received: 26 MAY 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (293K)

References

  • 1
    Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. J Parenter Enteral Nutr 2006; 30: 45–51.
  • 2
    UK national statistics, http://www.statistics.gov.uk/
  • 3
    Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain, 1950 to 2002. Lancet 2006; 367: 645.
  • 4
    Alter, MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6–S9.
  • 5
    Chan CY, Lee SD, Lo KJ. Legend of hepatitis B vaccination: the Taiwan experience. J Gastroenterol Hepatol 2004; 19: 121–126.
    Direct Link:
  • 6
    Banatvala J, Van Damme P, Emiroglu N. Hepatitis B immunisation in Britain: time to change? BMJ 2006; 332: 804–805.
  • 7
    Pérez-Peña R, Santora M. Hepatitis risk for East Asians in New York. New York Times, May 11, 2006.
  • 8
    Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. HEPATOLOGY 2006; 43: 915–922.
    Direct Link:
  • 9
    Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887–891.
  • 10
    AIDS epidemic update. UNAIDS/WHO, December 2005, http://www.unaids.org/epi/2005/doc/EPIupdate2005_pdf_en/Epi05_13_en.pdf
  • 11
    Hepatocellular carcinoma, UK Health Protection Agency Statistics 2005 “Mapping the Issues”.
  • 12
    World Health Organization statistics, http://www.who.int/countries/rus/en/
  • 13
    Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799–805.
  • 14
    Kramer JR, Giordano TP, Souchek J, El-Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005; 42: 309–314.
  • 15
    Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44: S65–S70.
  • 16
    Roskstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006; 44: S25–S27.
  • 17
    Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132–138.
  • 18
    Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004; 40: 1387–1395.
    Direct Link:
  • 19
    Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. HEPATOLOGY 2005; 42: 44–52.
    Direct Link:
  • 20
    Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508–514.
  • 21
    Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142–149.
  • 22
    http://www.oxha.org/meetings/knowledge/publications/05-meeting-documentation/05-meeting-powerpoint-slides/holdingfile3.doc
  • 23
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–1231.
  • 24
    Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. HEPATOLOGY 1997; 25: 108–111.
    Direct Link:
  • 25
    Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. HEPATOLOGY 2002; 35: 635–638.
    Direct Link:
  • 26
    Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005; 129: 1937–1943.
  • 27
    Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840–848.
  • 28
    Knobler H, Schattner A. TNF-α, chronic hepatitis C and diabetes: a novel triad. Q J Med 2005; 98: 1–6.
  • 29
    Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. HEPATOLOGY 2005; 41: 82–87.
    Direct Link:
  • 30
    Adinolfi LE, Gambardeall M, Andreana A, Tripodi MF, Utli R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. HEPATOLOGY 2001; 33: 1358–1364.
    Direct Link:
  • 31
    Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39: 1042–1048.
  • 32
    Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529–535.
  • 33
    Calling Time. The nation's drinking as a major health issue. Academy of Medical Sciences, March 2004.
  • 34
    Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42: 218–224.
  • 35
    Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620–626.
  • 36
    Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006; 12: 523–534.
    Direct Link:
  • 37
    Verran D, Kusyk T, Painter D, Fisher J, Koorey K, Strasser S, Stewart G, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9: 500–505.
    Direct Link:
  • 38
    Rinella ME, Alonso E, Rao S, Whittington P, Fryer J, Abecassis M, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001; 7: 409–414.
    Direct Link:
  • 39
    Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002; 8: 1114–1122.
    Direct Link:
  • 40
    Selzner M, Clavien P-A. Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. HEPATOLOGY 2000; 31: 35–42.
    Direct Link:
  • 41
    Middleton PF, Duffield M, Lynch SV, Padbury RT, House T, Stanton P, et al. Living donor liver transplantation–adult donor outcomes: a systematic review. Liver Transpl 2006; 12: 24–30.
    Direct Link:
  • 42
    Troisi R, Ricciardi S, Smeets P, Petrovic M, Van Maele G, Colle I, et al. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. Am J Transplant 2005; 5: 1397–1404.
    Direct Link:
  • 43
    International figures on organ donation and transplantation – 2004. Newsletter Transplant produced by the Transplant Committee of the Council of Europe. 2005 Sep; Vol. 10, no.1.
  • 44
    Hassanein T, Tofteng F, Brown RS Jr, McGuire BM, Lynch P, Mehta R, et al. Efficacy of albumin dialysis (MARS) in patients with cirrhosis and advanced grades of hepatic encephalopathy: A prospective, controlled randomized multicenter trial. HEPATOLOGY 2004; 40: 726A.
  • 45
    Williams R. The elusive goal of liver support—quest for the holy grail. Clin Med 2006. In press.
View Full Article (HTML) Get PDF (293K)